Search results for "burden"

showing 10 items of 393 documents

Exploring Why Global Health Needs Are Unmet by Public Research Efforts: The Potential Influences of Geography, Industry, and Publication Incentives

2019

Background It has been well established that research is not addressing health needs in a balanced way: much more research is conducted on diseases with more burden in high-income countries than on those with more burden in lower-income countries. In this study, we explore whether these imbalances persist and inquire about the possible influence of three factors: geography, industry, and publication incentives. Methods We use WHO data on the Global Burden of Disease as a proxy measure of health needs and bibliometric information as a proxy for research efforts. Scientific publications on diseases were collected from MEDLINE using MeSH terms to identify relevant publications. We used Web of …

Incentivebusiness.industryDevelopment economicsPublic sectorMEDLINEGlobal healthDeveloping countryDiseaseCitationbusinessDisease burdenSSRN Electronic Journal
researchProduct

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment…

2017

Abstract: Id1 promotes carcinogenesis and metastasis, and predicts prognosis of non-small cell lung cancer (NSCLC)-adenocarcionoma patients. We hypothesized that Id1 may play a critical role in lung cancer colonization of the liver by affecting both tumor cells and the microenvironment. Depleted levels of Id1 in LLC (Lewis lung carcinoma cells, LLC shId1) significantly reduced cell proliferation and migration in vitro. Genetic loss of Id1 in the host tissue (Id1(-/-) mice) impaired liver colonization and increased survival of Id1 animals. Histologically, the presence of Idl in tumor cells of liver metastasis was responsible for liver colonization. Microarray analysis comparing liver tumor n…

Inhibitor of Differentiation Protein 10301 basic medicineCancer ResearchPathologyLung NeoplasmsTime Factors10255 Clinic for Thoracic SurgeryVimentinmedicine.disease_causeMetastasisCarcinoma Lewis Lung0302 clinical medicineCell MovementCarcinoma Non-Small-Cell LungTumor Microenvironment1306 Cancer ResearchMice KnockoutTissue microarrayIntegrin beta1Liver NeoplasmsTumor BurdenGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesis2730 OncologySignal Transductionmedicine.medical_specialtyEpithelial-Mesenchymal TransitionLiver tumor610 Medicine & healthBiologyTransforming Growth Factor beta103 medical and health sciencesCell Line Tumor10049 Institute of Pathology and Molecular PathologymedicineAnimalsHumansVimentinEpithelial–mesenchymal transitionLung cancerCell ProliferationLewis lung carcinomamedicine.diseaseMice Inbred C57BL030104 developmental biologyCancer researchbiology.proteinHuman medicineSnail Family Transcription FactorsCarcinogenesisCancer Letters
researchProduct

Privātskološana un vecāku satraukums par izglītību Ķīnas "dubultās samazināšanas" politikas kontekstā

2022

Privātskološanas izplatība politikas veidotājiem rada grūtības. Ķīnas “Dubultās samazināšanas” politika paredz samazināt privātskološanu, lai atvieglotu slodzi skolēniem. Šī darba mērķis ir atrast galvenos cēloņus, kāpēc vecākiem ir trauksme par savu bērnu izglītību, meklējot saistību starp privātskološanu un vecāku satraukumu par bērnu izglītību. Pētījums ir balstīts uz literatūras izpēti un anketu, kurā piedalījās 656 vecāki, kuru bērni ir 1. līdz 12. klases skolēni Ķīnā. Rezultāti liecina, ka vecākiem jau bija raksturīga konkurences psiholoģija, un vecāku trauksme par bērnu izglītību vairāk veicina privātskološanas uzplaukumu, nevis privātskološana rada vecāku trauksmi par bērnu izglītīb…

Izglītības zinātnesprivate tutoringburden on studentsparents’ educational anxiety“Double Reduction” policycompetitive environment
researchProduct

Laparoscopic adrenalectomy for large adrenal masses: Single team experience

2014

Abstract Introduction Laparoscopic adrenalectomy is today considered the standard treatment for benign small adrenal tumors. An open question is the use of laparoscopy for large adrenal masses because of technical limitations and increased risk of malignancy. In this study we report our experience in laparoscopic adrenalectomy for adrenal masses larger than 6 cm. Methods Between January 2010 and December 2013 we performed 41 laparoscopic adrenalectomy. Fourteen of 41 patients (34,1%) were submitted to laparoscopic adrenalectomy for lesion >6 cm in size. All patients were submitted routinely to radiological and hormonal tests to indentify tumors characteristics. Results The patients treated …

Laparoscopic surgeryAdenomaAdultMalemedicine.medical_specialtymedicine.medical_treatmentOperative TimeAdrenal Gland NeoplasmsLaparoscopic adrenalectomyPheochromocytomaLaparoscopic surgeryMalignancyLesionMyelolipomamedicineHumansLaparoscopyAgedmedicine.diagnostic_testLaparoscopic adrenalectomybusiness.industryAdrenalectomyStandard treatmentLarge adrenal tumorsAdrenalectomyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTumor BurdenSettore MED/18 - Chirurgia GeneraleTreatment Outcomelaparoscopic adrenalectomy; laparoscopyRadiological weaponFemaleLaparoscopySurgerymedicine.symptombusinessFollow-Up StudiesInternational Journal of Surgery
researchProduct

Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure

2006

The potential of human papillomavirus (HPV) vaccines will only be realized if the vaccine candidates under development prove to be safe and effective and can be consistently produced to define quality standards. Whilst the responsibility for delivering a safe and effective product rests with the vaccine producer, a vaccine requires a license to allow it to be placed on the market. Licensure is based on an evaluation of the safety and efficacy profile of a vaccine candidate by national regulatory authorities, ideally on the basis of internationally agreed, science-based specifications and procedures. For vaccines, these international specifications are developed by the World Health Organizat…

LicensureGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industrymedia_common.quotation_subjectPublic Health Environmental and Occupational HealthMEDLINEHPV vaccinesPublic relationsProduct (business)Infectious DiseasesQuality safetyHumansMolecular MedicineMedicineQuality (business)Papillomavirus VaccinesbusinessLicensureLicenseDisease burdenmedia_commonVaccine
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Hepatitis C-related cirrhosis. Current status.

2016

Chronic hepatitis C virus (HCV) infection affects around 150 million people. It is a leading cause of liver related morbidity and mortality through its predisposition to liver fibrosis, cirrhosis and end-stage liver complications. New treatments based on direct-acting antivirals have opened a new era in the management of HCV cirrhosis. They allow for HCV eradication without substantial side effects in almost all cirrhotic patients, reducing the risk of hepatocellular carcinoma, liver decompensation and mortality. This review provides an update on HCV cirrhosis. The paper focuses on the disease burden and major progresses in the diagnosis, follow-up and treatment of this patient subgroup.

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver fibrosisGlobal HealthGastroenterologyAntiviral AgentsVirus03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansLiver decompensationDisease burdenbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationSpain030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationbusinessMedicina clinica
researchProduct

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

2022

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. Thes…

Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessHepatology
researchProduct

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct